Sen. John Boozman Buys Shares of Albemarle Corporation (NYSE:ALB)

Senator John Boozman (Republican-Arkansas) recently bought shares of Albemarle Corporation (NYSE:ALB). In a filing disclosed on June 16th, the Senator disclosed that they had bought between $1,001 and $15,000 in Albemarle stock on May 15th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BondBloxx Bloomberg Two Year Target Duration US Treasury ETF (NYSEARCA:XTWO) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of BondBloxx Bloomberg Five Year Target Duration US Treasury ETF (NYSEARCA:XFIV) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs Access Investment Grade Corporate Bond ETF (NYSEARCA:GIGB) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs Access Treasury 0-1 Year ETF (NYSEARCA:GBIL) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares Agency Bond ETF (NYSEARCA:AGZ) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares CMBS ETF (NYSEARCA:CMBS) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Janus Henderson Mortgage-Backed Securities ETF (NYSEARCA:JMBS) on 5/27/2026.

Albemarle Price Performance

Shares of ALB stock traded down $7.08 during trading hours on Thursday, reaching $140.76. The company had a trading volume of 3,046,348 shares, compared to its average volume of 2,514,232. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.21 and a current ratio of 2.07. The stock has a fifty day moving average of $178.65 and a 200-day moving average of $169.24. The company has a market capitalization of $16.60 billion, a price-to-earnings ratio of -41.28, a PEG ratio of 0.76 and a beta of 1.30. Albemarle Corporation has a 12-month low of $60.64 and a 12-month high of $221.00.

Albemarle (NYSE:ALB) last announced its quarterly earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $1.71. Albemarle had a negative net margin of 5.00% and a positive return on equity of 5.22%. The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. During the same quarter last year, the firm earned ($0.18) EPS. The business’s revenue was up 32.7% compared to the same quarter last year. On average, equities analysts anticipate that Albemarle Corporation will post 12.39 earnings per share for the current year.

Albemarle Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Friday, June 12th will be paid a dividend of $0.405 per share. This represents a $1.62 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Friday, June 12th. Albemarle’s dividend payout ratio is currently -47.51%.

Insider Transactions at Albemarle

In other Albemarle news, CEO J Kent Masters sold 16,393 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $183.72, for a total transaction of $3,011,721.96. Following the completion of the sale, the chief executive officer directly owned 87,519 shares of the company’s stock, valued at approximately $16,078,990.68. This trade represents a 15.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.42% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALB. Argus increased their target price on shares of Albemarle from $185.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Mizuho boosted their target price on Albemarle from $185.00 to $205.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Berenberg Bank lifted their price objective on Albemarle from $153.00 to $192.00 and gave the company a “hold” rating in a research note on Tuesday, June 2nd. Scotiabank increased their price target on shares of Albemarle from $200.00 to $215.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings upgraded shares of Albemarle from a “sell (d-)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $202.54.

Institutional Trading of Albemarle

Hedge funds and other institutional investors have recently bought and sold shares of the business. MH & Associates Securities Management Corp ADV acquired a new position in shares of Albemarle in the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Albemarle in the fourth quarter valued at $34,000. Torren Management LLC acquired a new position in Albemarle in the fourth quarter valued at $38,000. Sound Income Strategies LLC raised its holdings in shares of Albemarle by 190.1% in the first quarter. Sound Income Strategies LLC now owns 293 shares of the specialty chemicals company’s stock valued at $52,000 after buying an additional 192 shares during the last quarter. Finally, Root Financial Partners LLC grew its holdings in shares of Albemarle by 121.5% during the fourth quarter. Root Financial Partners LLC now owns 299 shares of the specialty chemicals company’s stock worth $42,000 after buying an additional 164 shares during the last quarter. 92.87% of the stock is currently owned by institutional investors and hedge funds.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.